Cart
sales@molnova.com
Otilimab
CAS No. 1638332-55-4
Otilimab( —— )
Catalog No. M36826 CAS No. 1638332-55-4
Otilimab (GSK 3196165) is a humanized monoclonal antibody against granulocyt-macrophage colony-stimulating factor (GM-CSF).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 306 | In Stock |
|
| 10MG | 522 | In Stock |
|
| 25MG | 829 | In Stock |
|
| 50MG | 1088 | In Stock |
|
| 100MG | 1469 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOtilimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionOtilimab (GSK 3196165) is a humanized monoclonal antibody against granulocyt-macrophage colony-stimulating factor (GM-CSF).
-
DescriptionOtilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) humanized monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetCSF1R
-
RecptorCSF-1R
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1638332-55-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Senolt L. Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. F1000Res. 2019 Aug 30;8:F1000 Faculty Rev-1549.?
molnova catalog
related products
-
c-Fms-IN-13
c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50 = 17 nM) and serves as an anti-inflammatory agent.
-
c-FMS-IN-8
c-FMS-IN-8 is a potent, selective c-FMS kinase inhibitor with IC50 of 0.8 nM, shows activity in collagen-induced model of arthritis in mice.
-
Plonmarlimab
Plonmarlimab (TJ003234) is an anti-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody with potential antiviral activity for the study of immune diseases and novel coronavirus infections.
